Overview
An RSV Vaccine for Pregnant Women Research Study is Enrolling Now
Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in infants—and most RSV-related deaths in hospitals happen in babies under 6 months. This research study is testing an RSV vaccine given during pregnancy. Your experience can make a difference!
About the Study
Clinical research helps us understand how well an RSV vaccine protects newborns when given during pregnancy. It’s essential for learning how long the protection lasts, whether repeat doses are needed in future pregnancies, and how to ensure the best outcomes for both mothers and babies. This research leads to better prevention strategies and helps protect infants from serious illness, hospitalizations, and complications caused by RSV.
Play a crucial role in advancing research on RSV vaccines and help researchers develop future treatments!
Who Can Join
To qualify, you must meet the following conditions:
- Between 18 and 49 years old and currently pregnant with one baby
- Between 24 and 36 weeks pregnant at the time of joining
- Received one dose of the RSV vaccine during a previous pregnancy
- Currently receiving routine prenatal care
- Had a fetal ultrasound at 18 weeks or later showing no major issues
- Have no known complications or high-risk conditions
- Tested negative for HIV, syphilis, and hepatitis B during this pregnancy
*Other conditions may apply
Not sure if you qualify? That’s okay.
A member of our recruitment team will review your medical history and medications with you to see if this study may be right for you.
What to Expect
Study Duration:
Up to 10 months
This includes the time from vaccination during pregnancy (between 24 to 36 weeks’ gestation) until approximately 6 months after the baby is born.
The baby will participate in the study for approximately 6 months after birth.
Study Visits:
Up to 4 visits for mom and up to 3 visits for baby
The study involves a combination of site visits, telephone calls, and hospital/home assessments.
Compensation:
Participants may receive compensation up to $648